Page last updated: 2024-12-07

7 alpha-hydroxy-4-cholesten-3-one

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

7 alpha-hydroxy-4-cholesten-3-one: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

7alpha-hydroxycholest-4-en-3-one : A cholestanoid consisting of a cholesterol core having an oxo group at the 3-position, a C=C bond at the 4,5-position and an alpha-hydroxy group at the 7-position. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID123743
CHEMBL ID4285345
CHEBI ID17899
SCHEMBL ID178019
MeSH IDM0043344

Synonyms (39)

Synonym
BIDD:PXR0048
7-hydroxycholest-4-en-3-one
7a-hydroxy-cholestene-3-one
CHEBI:17899
cholest-4-en-7alpha-ol-3-one
3862-25-7
7alpha-hydroxy-4-cholesten-3-one
4-cholesten-7alpha-ol-3-one
7alpha-hydroxycholest-4-en-3-one
C05455
LMST04030123
(7r,8s,9s,10r,13r,14s,17r)-7-hydroxy-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one
4-cholesten-7-alpha-ol-3-one
7-hydroxy-4-cholesten-3-one
cholest-4-en-3-one, 7-hydroxy-, (7alpha)-
7 alpha-hydroxy-4-cholesten-3-one
7|a-hydroxy-4-cholesten-3-one
SCHEMBL178019
(7r,8s,9s,10r,13r,14s,17r)-7-hydroxy-10,13-dimethyl-17-((r)-6-methylheptan-2-yl)-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3(2h)-one
DTXSID10191938
AKOS027320761
7alpha-hydroxy-4-cholesten-3-one, >=95.0% (hplc)
7a-hydroxy-4-cholesten-3-one-12alpha
7-alpha-hydroxycholest-4-en-3-one
7-a-hydroxycholest-4-en-3-one
7-alpha-hydroxy-4-cholesten-3-one
7 alpha-3ox-c
(7r,8s,9s,10r,13r,17r)-7-hydroxy-10,13-dimethyl-17-((r)-6-methylheptan-2-yl)-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3(2h)-one
Q4644247
HY-113259
7-a-hydroxy-4-cholesten-3-one
CS-0059449
CHEMBL4285345
(7alpha)-7-hydroxycholest-4-en-3-one
7 alpha -hydroxy-4-cholesten-3-one
MS-26816
GLXC-26103
7?-hydroxy-4-cholesten-3-one
PD080599

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"Pathogenesis in non-alcoholic steatohepatitis (NASH) involves abnormal cholesterol metabolism and hepatic accumulation of toxic free cholesterol."( Safety, tolerability and pharmacodynamics of apical sodium-dependent bile acid transporter inhibition with volixibat in healthy adults and patients with type 2 diabetes mellitus: a randomised placebo-controlled trial.
Acevedo, L; Dorenbaum, A; Gedulin, B; Keller, BT; Kennedy, CA; Levin, N; Palmer, M; Tiessen, RG; van Vliet, AA, 2018
)
0.48
" No deaths or treatment-related serious adverse events were reported."( Safety, tolerability and pharmacodynamics of apical sodium-dependent bile acid transporter inhibition with volixibat in healthy adults and patients with type 2 diabetes mellitus: a randomised placebo-controlled trial.
Acevedo, L; Dorenbaum, A; Gedulin, B; Keller, BT; Kennedy, CA; Levin, N; Palmer, M; Tiessen, RG; van Vliet, AA, 2018
)
0.48
"Accumulation of toxic free cholesterol in hepatocytes may cause hepatic inflammation and fibrosis."( A randomised, double-blind, placebo-controlled phase 1 study of the safety, tolerability and pharmacodynamics of volixibat in overweight and obese but otherwise healthy adults: implications for treatment of non-alcoholic steatohepatitis.
Bliss, C; Jennings, L; Martin, P; Palmer, M; Silberg, DG, 2018
)
0.48
"All 84 randomised participants (volixibat, 63; placebo, 21) completed the study, with no serious adverse events at doses of up to 80 mg per day (maximum assessed dose)."( A randomised, double-blind, placebo-controlled phase 1 study of the safety, tolerability and pharmacodynamics of volixibat in overweight and obese but otherwise healthy adults: implications for treatment of non-alcoholic steatohepatitis.
Bliss, C; Jennings, L; Martin, P; Palmer, M; Silberg, DG, 2018
)
0.48
" No serious adverse events and no adverse events leading to study discontinuation or withdrawal were reported."( Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Evaluations Following Single Oral Doses of GSK2330672 in Healthy Japanese Volunteers.
Endo, A; Ino, H; Kendrick, S; Numachi, Y; Ogura, H; Wakamatsu, A, 2019
)
0.51

Pharmacokinetics

ExcerptReferenceRelevance
" Volixibat was minimally absorbed; serum levels were rarely quantifiable at any dose or sampling time point, thereby precluding pharmacokinetic analyses."( A randomised, double-blind, placebo-controlled phase 1 study of the safety, tolerability and pharmacodynamics of volixibat in overweight and obese but otherwise healthy adults: implications for treatment of non-alcoholic steatohepatitis.
Bliss, C; Jennings, L; Martin, P; Palmer, M; Silberg, DG, 2018
)
0.48
" Pharmacodynamic observations included a tendency for total serum bile acids to reduce and for serum 7α-hydroxy-4-cholesten-3-one, a key intermediate of bile acid synthesis, to increase with increasing doses of GSK2330672."( Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Evaluations Following Single Oral Doses of GSK2330672 in Healthy Japanese Volunteers.
Endo, A; Ino, H; Kendrick, S; Numachi, Y; Ogura, H; Wakamatsu, A, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" Based on the assessment of predefined safety events, volixibat dosing was either escalated or reduced."( A randomised, double-blind, placebo-controlled phase 1 study of the safety, tolerability and pharmacodynamics of volixibat in overweight and obese but otherwise healthy adults: implications for treatment of non-alcoholic steatohepatitis.
Bliss, C; Jennings, L; Martin, P; Palmer, M; Silberg, DG, 2018
)
0.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
7alpha-hydroxy steroidA 7-hydroxy steroid in which the hydroxy group at position 7 has an alpha-configuration.
cholestanoidAny steroid based on a cholestane skeleton and its derivatives.
3-oxo-Delta(4) steroidA 3-oxo steroid conjugated to a C=C double bond at the alpha,beta position.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (22)

PathwayProteinsCompounds
Metabolism14961108
Metabolism of lipids500463
Metabolism of steroids111135
Bile acid and bile salt metabolism3171
Synthesis of bile acids and bile salts2068
Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol1644
Biological oxidations150276
Phase I - Functionalization of compounds69175
Cytochrome P450 - arranged by substrate type30110
Endogenous sterols1838
Sterols are 12-hydroxylated by CYP8B1011
Bile Acid Biosynthesis1761
Congenital Bile Acid Synthesis Defect Type II1761
Congenital Bile Acid Synthesis Defect Type III1761
Familial Hypercholanemia (FHCA)1761
Zellweger Syndrome1761
Cerebrotendinous Xanthomatosis (CTX)1761
27-Hydroxylase Deficiency1761
Disorders of bile acid synthesis and biliary transport1840
bile acid biosynthesis, neutral pathway644
Biochemical pathways: part I0466
Oxysterols derived from cholesterol3831

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1423559Cytoprotective activity against H2O2-induced oxidative injury in rat PC12 cells assessed as reduction in cell viability at 10 uM pretreated for 24 hrs followed by 350 uM H2O2 challenge measured after 24 hrs by MTT assay2018Journal of natural products, 11-26, Volume: 81, Issue:11
A Steroid-Type Antioxidant Targeting the Keap1/Nrf2/ARE Signaling Pathway from the Soft Coral Dendronephthya gigantea.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (132)

TimeframeStudies, This Drug (%)All Drugs %
pre-199013 (9.85)18.7374
1990's22 (16.67)18.2507
2000's30 (22.73)29.6817
2010's62 (46.97)24.3611
2020's5 (3.79)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 26.23

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index26.23 (24.57)
Research Supply Index5.09 (2.92)
Research Growth Index4.83 (4.65)
Search Engine Demand Index32.99 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (26.23)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials28 (20.90%)5.53%
Reviews4 (2.99%)6.00%
Case Studies1 (0.75%)4.05%
Observational2 (1.49%)0.25%
Other99 (73.88%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]